GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB3 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity ...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Arexvy is the first RSV vaccine approved by the FDA for the prevention of lower respiratory tract disease in individuals 60 years of age and older. The vaccine reduced the risk of...
GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB3 days ago · PHILADELPHIA-- (BUSINESS WIRE)-- #Adult --GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant ...
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · AREXVY is the first RSV vaccine for adults aged 50-59 who are at increased risk of severe RSV outcomes, such as COPD, asthma, heart failure and diabetes. The vaccine is also approved for adults 60 and older and has a phase III trial ongoing for adults 18-49 and immunocompromised adults.
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · GSK announced positive preliminary results from its phase III trial evaluating AREXVY in adults aged 50 to 59 at increased risk for RSV disease. The vaccine is approved for adults 60 and older and GSK plans to submit data for potential label expansion in …
WEBGSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk. Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in …
GSK's Respiratory Syncytial Virus Vaccine Given Together With …
WEB3 days ago · Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of a News Today's news
GSK shares positive data for AREXVY, its respiratory syncytial virus ...
WEBJun 21, 2023 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants...
- Some results have been removed
Skip to content